-
1
-
-
33846857559
-
Heart disease and stroke statistics-2007 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee
-
Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115: e69-e171.
-
(2007)
Circulation
, vol.115
-
-
Rosamond, W.1
Flegal, K.2
Friday, G.3
Furie, K.4
Go, A.5
Greenlund, K.6
-
2
-
-
22744448612
-
HMG-CoA reductase inhibitor pharmacogenomics: Overview and implications for practice
-
Zineh I. HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice. Future Cardiol 2005; 1: 191-206.
-
(2005)
Future Cardiol
, vol.1
, pp. 191-206
-
-
Zineh, I.1
-
3
-
-
33746799030
-
Clinical implications of pharma-cogenomics of statin treatment
-
Mangravite LM, Thorn CF, Krauss RM. Clinical implications of pharma-cogenomics of statin treatment. Pharmacogenomics J 2006; 6: 360-374.
-
(2006)
Pharmacogenomics J
, vol.6
, pp. 360-374
-
-
Mangravite, L.M.1
Thorn, C.F.2
Krauss, R.M.3
-
4
-
-
16644386102
-
Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors
-
Tachibana-Iimori R, Tabara Y, Kusuhara H, Kohara K, Kawamoto R, Nakura J et al. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet 2004; 19: 375-380.
-
(2004)
Drug Metab Pharmacokinet
, vol.19
, pp. 375-380
-
-
Tachibana-Iimori, R.1
Tabara, Y.2
Kusuhara, H.3
Kohara, K.4
Kawamoto, R.5
Nakura, J.6
-
5
-
-
26244432388
-
Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
-
Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
-
(2005)
Lancet
, vol.366
, pp. 1267-1278
-
-
Baigent, C.1
Keech, A.2
Kearney, P.M.3
Blackwell, L.4
Buck, G.5
Pollicino, C.6
-
6
-
-
0034723758
-
The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals
-
Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459-467.
-
(2000)
Arch Intern Med
, vol.160
, pp. 459-467
-
-
Pearson, T.A.1
Laurora, I.2
Chu, H.3
Kafonek, S.4
-
7
-
-
34447307653
-
The broad spectrum of statin myopathy: From myalgia to rhabdomyolysis
-
Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol 2007; 18: 401-408.
-
(2007)
Curr Opin Lipidol
, vol.18
, pp. 401-408
-
-
Harper, C.R.1
Jacobson, T.A.2
-
8
-
-
67249111853
-
Narrative review: Statin-related myopathy
-
Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med 2009; 150: 858-868.
-
(2009)
Ann Intern Med
, vol.150
, pp. 858-868
-
-
Joy, T.R.1
Hegele, R.A.2
-
9
-
-
33645881669
-
Statin safety: A systematic review
-
Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97: 52C-60C.
-
(2006)
Am J Cardiol
, vol.97
-
-
Law, M.1
Rudnicka, A.R.2
-
10
-
-
57649158467
-
Molecular basis of statin-associated myopathy
-
Vaklavas C, Chatzizisis YS, Ziakas A, Zamboulis C, Giannoglou GD. Molecular basis of statin-associated myopathy. Atherosclerosis 2009; 202: 18-28.
-
(2009)
Atherosclerosis
, vol.202
, pp. 18-28
-
-
Vaklavas, C.1
Chatzizisis, Y.S.2
Ziakas, A.3
Zamboulis, C.4
Giannoglou, G.D.5
-
11
-
-
35748962429
-
The safety of statins in clinical practice
-
Armitage J. The safety of statins in clinical practice. Lancet 2007; 370: 1781-1790.
-
(2007)
Lancet
, vol.370
, pp. 1781-1790
-
-
Armitage, J.1
-
12
-
-
33845420011
-
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
-
Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006; 80: 565-581.
-
(2006)
Clin Pharmacol Ther
, vol.80
, pp. 565-581
-
-
Neuvonen, P.J.1
Niemi, M.2
Backman, J.T.3
-
14
-
-
2042539351
-
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: What's it all about?
-
Kim RB. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: what's it all about? Clin Pharmacol Ther 2004; 75: 381-385.
-
(2004)
Clin Pharmacol Ther
, vol.75
, pp. 381-385
-
-
Kim, R.B.1
-
15
-
-
56149110125
-
Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs
-
Maeda K, Sugiyama Y. Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab Pharmacokinet 2008; 23: 223-235.
-
(2008)
Drug Metab Pharmacokinet
, vol.23
, pp. 223-235
-
-
Maeda, K.1
Sugiyama, Y.2
-
16
-
-
22544454498
-
Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells
-
Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 2005; 15: 513-522.
-
(2005)
Pharmacogenet Genomics
, vol.15
, pp. 513-522
-
-
Kameyama, Y.1
Yamashita, K.2
Kobayashi, K.3
Hosokawa, M.4
Chiba, K.5
-
17
-
-
42149127614
-
The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: The contribution of transporting activity changes by SLCO1B1*15
-
Deng JW, Song IS, Shin HJ, Yeo CW, Cho DY, Shon JH et al. The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics 2008; 18: 424-433.
-
(2008)
Pharmacogenet Genomics
, vol.18
, pp. 424-433
-
-
Deng, J.W.1
Song, I.S.2
Shin, H.J.3
Yeo, C.W.4
Cho, D.Y.5
Shon, J.H.6
-
18
-
-
36148953896
-
Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin
-
Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2007; 82: 726-733.
-
(2007)
Clin Pharmacol Ther
, vol.82
, pp. 726-733
-
-
Pasanen, M.K.1
Fredrikson, H.2
Neuvonen, P.J.3
Niemi, M.4
-
19
-
-
67650753944
-
Genetic polymorphisms of uptake (OATP1B1 1B3) and efflux (MRP2 BCRP) transporters: Implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs
-
Ieiri I, Higuchi S, Sugiyama Y. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol 2009; 5: 703-729.
-
(2009)
Expert Opin Drug Metab Toxicol
, vol.5
, pp. 703-729
-
-
Ieiri, I.1
Higuchi, S.2
Sugiyama, Y.3
-
20
-
-
34548103493
-
Role of OATP transporters in the disposition of drugs
-
Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 2007; 8: 787-802.
-
(2007)
Pharmacogenomics
, vol.8
, pp. 787-802
-
-
Niemi, M.1
-
21
-
-
56449116103
-
ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin
-
Keskitalo JE, Kurkinen KJ, Neuvoneni PJ, Niemi M. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther 2008; 84: 457-461.
-
(2008)
Clin Pharmacol Ther
, vol.84
, pp. 457-461
-
-
Keskitalo, J.E.1
Kurkinen, K.J.2
Neuvoneni, P.J.3
Niemi, M.4
-
22
-
-
68449085764
-
No significant effect of ABCB1 haplotypes on the pharma-cokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin
-
Keskitalo JE, Kurkinen KJ, Neuvonen M, Backman JT, Neuvonen PJ, Niemi M. No significant effect of ABCB1 haplotypes on the pharma-cokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. Br J Clin Pharmacol 2009; 68: 207-213.
-
(2009)
Br J Clin Pharmacol
, vol.68
, pp. 207-213
-
-
Keskitalo, J.E.1
Kurkinen, K.J.2
Neuvonen, M.3
Backman, J.T.4
Neuvonen, P.J.5
Niemi, M.6
-
24
-
-
33748042671
-
Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3- methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions
-
Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006; 112: 71-105.
-
(2006)
Pharmacol Ther
, vol.112
, pp. 71-105
-
-
Shitara, Y.1
Sugiyama, Y.2
-
25
-
-
33750319402
-
Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravas-tatin pharmacokinetics
-
Niemi M, Arnold KA, Backman JT, Pasanen MK, Godtel-Armbrust U, Wojnowski L et al. Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravas-tatin pharmacokinetics. Pharmacogenet Genomics 2006; 16: 801-808.
-
(2006)
Pharmacogenet Genomics
, vol.16
, pp. 801-808
-
-
Niemi, M.1
Arnold, K.A.2
Backman, J.T.3
Pasanen, M.K.4
Godtel-Armbrust, U.5
Wojnowski, L.6
-
26
-
-
34447335619
-
Effect of drug transporter genotypes on pravastatin disposition in European-and African-American participants
-
Ho RH, Choi L, Lee W, Mayo G, Schwarz UI, Tirona RG et al. Effect of drug transporter genotypes on pravastatin disposition in European-and African-American participants. Pharmacogenet Genomics 2007; 17: 647-656.
-
(2007)
Pharmacogenet Genomics
, vol.17
, pp. 647-656
-
-
Ho, R.H.1
Choi, L.2
Lee, W.3
Mayo, G.4
Schwarz, U.I.5
Tirona, R.G.6
-
27
-
-
67651172794
-
ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin
-
Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2009; 86: 197-203.
-
(2009)
Clin Pharmacol Ther
, vol.86
, pp. 197-203
-
-
Keskitalo, J.E.1
Zolk, O.2
Fromm, M.F.3
Kurkinen, K.J.4
Neuvonen, P.J.5
Niemi, M.6
-
28
-
-
33747884712
-
Role of BCRP 421C4A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males
-
Zhang W, Yu BN, He YJ, Fan L, Li Q, Liu ZQ et al. Role of BCRP 421C4A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta 2006; 373: 99-103.
-
(2006)
Clin Chim Acta
, vol.373
, pp. 99-103
-
-
Zhang, W.1
Yu, B.N.2
He, Y.J.3
Fan, L.4
Li, Q.5
Liu, Z.Q.6
-
29
-
-
35448946484
-
SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavas-tatin in healthy volunteers
-
Ieiri I, Suwannakul S, Maeda K, Uchimaru H, Hashimoto K, Kimura M et al. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavas-tatin in healthy volunteers. Clin Pharmacol Ther 2007; 82: 541-547.
-
(2007)
Clin Pharmacol Ther
, vol.82
, pp. 541-547
-
-
Ieiri, I.1
Suwannakul, S.2
Maeda, K.3
Uchimaru, H.4
Hashimoto, K.5
Kimura, M.6
-
30
-
-
0033601257
-
A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutar-yl-CoA reductase inhibitor transporters
-
Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutar-yl-CoA reductase inhibitor transporters. J Biol Chem 1999; 274: 37161-37168.
-
(1999)
J Biol Chem
, vol.274
, pp. 37161-37168
-
-
Hsiang, B.1
Zhu, Y.2
Wang, Z.3
Wu, Y.4
Sasseville, V.5
Yang, W.P.6
-
31
-
-
25144450046
-
Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport
-
Ito K, Suzuki H, Horie T, Sugiyama Y. Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm Res 2005; 22: 1559-1577.
-
(2005)
Pharm Res
, vol.22
, pp. 1559-1577
-
-
Ito, K.1
Suzuki, H.2
Horie, T.3
Sugiyama, Y.4
-
32
-
-
4644301418
-
Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: Analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil
-
Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)- mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 2004; 311: 228-236.
-
(2004)
J Pharmacol Exp Ther
, vol.311
, pp. 228-236
-
-
Shitara, Y.1
Hirano, M.2
Sato, H.3
Sugiyama, Y.4
-
33
-
-
0002186061
-
Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C (abstract)
-
Brown CDA, Windass A, Bleasby K, Lauffart B. Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C (abstract). Atheroscler Suppl 2001; 2: 90.
-
(2001)
Atheroscler Suppl
, vol.2
, pp. 90
-
-
Brown, C.D.A.1
Windass, A.2
Bleasby, K.3
Lauffart, B.4
-
35
-
-
0035929574
-
Polymorphisms in OATP-C: Identification of multiple allelic variants associated with altered transport activity among European-and African-Americans
-
Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European-and African-Americans. J Biol Chem 2001; 276: 35669-35675.
-
(2001)
J Biol Chem
, vol.276
, pp. 35669-35675
-
-
Tirona, R.G.1
Leake, B.F.2
Merino, G.3
Kim, R.B.4
-
36
-
-
25844458977
-
Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment
-
Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005; 78: 330-341.
-
(2005)
Clin Pharmacol Ther
, vol.78
, pp. 330-341
-
-
Lee, E.1
Ryan, S.2
Birmingham, B.3
Zalikowski, J.4
March, R.5
Ambrose, H.6
-
37
-
-
0038209381
-
Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics
-
DOI 10.1016/S0009-9236(03)00060-2
-
Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 2003; 73: 554-565. (Pubitemid 37249126)
-
(2003)
Clinical Pharmacology and Therapeutics
, vol.73
, Issue.6
, pp. 554-565
-
-
Nishizato, Y.1
Ieiri, I.2
Suzuki, H.3
Kimura, M.4
Kawabata, K.5
Hirota, T.6
Takane, H.7
Irie, S.8
Kusuhara, H.9
Urasaki, Y.10
Urae, A.11
Higuchi, S.12
Otsubo, K.13
Sugiyama, Y.14
-
38
-
-
33745031039
-
Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population
-
Pasanen MK, Backman JT, Neuvonen PJ, Niemi M. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. Eur J Clin Pharmacol 2006; 62: 409-415.
-
(2006)
Eur J Clin Pharmacol
, vol.62
, pp. 409-415
-
-
Pasanen, M.K.1
Backman, J.T.2
Neuvonen, P.J.3
Niemi, M.4
-
40
-
-
33644666953
-
An association study of 43 SNPs in 16 candidate genes with atorvastatin response
-
Thompson JF, Man M, Johnson KJ, Wood LS, Lira ME, Lloyd DB et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 2005; 5: 352-358.
-
(2005)
Pharmacogenomics J
, vol.5
, pp. 352-358
-
-
Thompson, J.F.1
Man, M.2
Johnson, K.J.3
Wood, L.S.4
Lira, M.E.5
Lloyd, D.B.6
-
41
-
-
33646536542
-
Drug and bile acid transporters in rosuvastatin hepatic uptake: Function, expression, and pharmacogenetics
-
Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 2006; 130: 1793-1806.
-
(2006)
Gastroenterology
, vol.130
, pp. 1793-1806
-
-
Ho, R.H.1
Tirona, R.G.2
Leake, B.F.3
Glaeser, H.4
Lee, W.5
Lemke, C.J.6
-
42
-
-
0036073404
-
Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): Allele frequencies in the Japanese population and functional analysis
-
Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y et al. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 2002; 302: 804-813.
-
(2002)
J Pharmacol Exp Ther
, vol.302
, pp. 804-813
-
-
Nozawa, T.1
Nakajima, M.2
Tamai, I.3
Noda, K.4
Nezu, J.5
Sai, Y.6
-
43
-
-
9244254743
-
Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C)
-
Iwai M, Suzuki H, Ieiri I, Otsubo K, Sugiyama Y. Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics 2004; 14: 749-757.
-
(2004)
Pharmacogenetics
, vol.14
, pp. 749-757
-
-
Iwai, M.1
Suzuki, H.2
Ieiri, I.3
Otsubo, K.4
Sugiyama, Y.5
-
44
-
-
18644368162
-
A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter
-
Michalski C, Cui Y, Nies AT, Nuessler AK, Neuhaus P, Zanger UM et al. A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. J Biol Chem 2002; 277: 43058-43063.
-
(2002)
J Biol Chem
, vol.277
, pp. 43058-43063
-
-
Michalski, C.1
Cui, Y.2
Nies, A.T.3
Nuessler, A.K.4
Neuhaus, P.5
Zanger, U.M.6
-
45
-
-
33646198187
-
Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin
-
Igel M, Arnold KA, Niemi M, Hofmann U, Schwab M, Lutjohann D et al. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin Pharmacol Ther 2006; 79: 419-426.
-
(2006)
Clin Pharmacol Ther
, vol.79
, pp. 419-426
-
-
Igel, M.1
Arnold, K.A.2
Niemi, M.3
Hofmann, U.4
Schwab, M.5
Lutjohann, D.6
-
46
-
-
33749049136
-
SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin
-
Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther 2006; 80: 356-366.
-
(2006)
Clin Pharmacol Ther
, vol.80
, pp. 356-366
-
-
Niemi, M.1
Pasanen, M.K.2
Neuvonen, P.J.3
-
47
-
-
49949104757
-
SLCO1B1 variants and statin-induced myopathy-a genomewide study
-
Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 2008; 359: 789-799.
-
(2008)
N Engl J Med
, vol.359
, pp. 789-799
-
-
Link, E.1
Parish, S.2
Armitage, J.3
Bowman, L.4
Heath, S.5
Matsuda, F.6
-
48
-
-
2042469487
-
Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics
-
Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 2004; 75: 415-421.
-
(2004)
Clin Pharmacol Ther
, vol.75
, pp. 415-421
-
-
Mwinyi, J.1
Johne, A.2
Bauer, S.3
Roots, I.4
Gerloff, T.5
-
49
-
-
33646205286
-
Effects of organic anion transporting polypeptide 1B1 haplotype on pharmaco-kinetics of pravastatin, valsartan, and temocapril
-
Maeda K, Ieiri I, Yasuda K, Fujino A, Fujiwara H, Otsubo K et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmaco-kinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther 2006; 79: 427-439.
-
(2006)
Clin Pharmacol Ther
, vol.79
, pp. 427-439
-
-
Maeda, K.1
Ieiri, I.2
Yasuda, K.3
Fujino, A.4
Fujiwara, H.5
Otsubo, K.6
-
50
-
-
56149115550
-
Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacody-namics of repaglinide and nateglinide
-
Kalliokoski A, Backman JT, Neuvonen PJ, Niemi M. Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacody-namics of repaglinide and nateglinide. Pharmacogenet Genomics 2008; 18: 937-942.
-
(2008)
Pharmacogenet Genomics
, vol.18
, pp. 937-942
-
-
Kalliokoski, A.1
Backman, J.T.2
Neuvonen, P.J.3
Niemi, M.4
-
51
-
-
33748645938
-
Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy
-
Takane H, Miyata M, Burioka N, Shigemasa C, Shimizu E, Otsubo K et al. Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy. J Hum Genet 2006; 51: 822-826.
-
(2006)
J Hum Genet
, vol.51
, pp. 822-826
-
-
Takane, H.1
Miyata, M.2
Burioka, N.3
Shigemasa, C.4
Shimizu, E.5
Otsubo, K.6
-
52
-
-
34548009561
-
SLCO1B1 521T-C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients
-
Zhang W, Chen BL, Ozdemir V, He YJ, Zhou G, Peng DD et al. SLCO1B1 521T-C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. Br J Clin Pharmacol 2007; 64: 346-352.
-
(2007)
Br J Clin Pharmacol
, vol.64
, pp. 346-352
-
-
Zhang, W.1
Chen, B.L.2
Ozdemir, V.3
He, Y.J.4
Zhou, G.5
Peng, D.D.6
-
53
-
-
0037031061
-
MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial
-
Heart Protection Study Collaborative Group
-
Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
-
(2002)
Lancet
, vol.360
, pp. 7-22
-
-
|